Shanghai WD Pharmaceutical Co., Ltd. and Boehringer Ingelheim Greater China announced a drug delivery technology development project



Recently, Shanghai WD Pharmaceutical Co., Ltd. (hereinafter referred to as WD Pharma) and Boehringer Ingelheim China (hereinafter referred to as Boehringer Ingelheim) jointly announced that Boehringer Ingelheim will leverage WD Pharma's AcuSiS® technology platform to explore innovative drug delivery techniques to address the clinical dosing challenges faced by pediatric and geriatric patients, thereby improving medication compliance.

The development of formulations for pediatric and geriatric patients has long been hampered by issues such as swallowing difficulties and palatability concerns, resulting in a lack of specialized formulations. Existing dosage forms can only partially address swallowing issues but often introduce palatability issues. WD Pharma's proprietary universal technology platform, AcuSiS®, can accommodate various dosage forms such as granules, pellets, and microtablets, providing high flexibility. This novel solid oral dosage form simultaneously addresses both swallowing and palatability issues, requires no preparation, is easy to use, and offers discreet dosing that can alleviate patients' fear of medication and improve medication compliance.



Dr. Liang C. Dong, CEO of WD Pharma, stated, "WD Pharma is honored to enter into this collaboration with Boehringer Ingelheim. Since its inception, WD Pharma has been deeply committed to the development of innovative drug delivery systems and is dedicated to identifying and addressing unmet clinical needs to provide patients with the latest medical technologies and the best treatment experience. AcuSiS®, as a novel oral drug delivery device capable of simultaneously addresses swallowing and palatability issues and achieve the goal of 'medicine without bitterness and dosing without hands,' while reducing research and development pressures and accelerating clinical trials. Through this collaboration with Boehringer Ingelheim, we hope to find a  fast and efficient way to develop pediatric and geriatric products".

Dr. Zhang Wei, Senior Vice President of Research and Development and Medical Affairs for Boehringer Ingelheim Greater China, commented, "Boehringer Ingelheim has always adhered to a patient-centric innovation strategy in research and development. We not only focus on the discovery and clinical research of innovative drugs, but also pay close attention to the needs of different patient groups in terms of drug delivery methods. Through this collaboration with WD Pharma, we hope to innovate in the area of drug delivery and bring innovative dosing methods to patients with swallowing difficulties. Furthermore, we aim to apply this technology to Boehringer Ingelheim's global drug development efforts, fulfilling our commitment to “developing innovation in China for the global community".

About WD Pharma:

Shanghai WD Pharmaceutical Co., Ltd. was established in January 2016 in Shanghai Zhangjiang Hi-Tech Park. The company specializes in developing innovative drug delivery technology platforms that integrate active pharmaceutical ingredients and medical devices. It is committed to developing novel products with global intellectual property rights and significant clinical advantages. WD Pharma has developed several technology platforms and a diversified product pipeline. Currently, the company has developed proprietary drug/device combination delivery systems. Four clinical-stage products cover the full spectrum of Parkinson's disease treatment.

About Boehringer Ingelheim Greater China:

Headquartered in Ingelheim, Germany, Boehringer Ingelheim is one of the world's leading biopharmaceutical companies, with more than 53,000 employees worldwide. Our core business is to develop new and better drugs for humans and animals. Boehringer Ingelheim Greater China is headquartered in Shanghai and currently employs more than 3,800 people across the country. Its core businesses include human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. In recent years, Boehringer Ingelheim has achieved significant growth in China and has been recognized as a "Top Employer in China" for ten consecutive years. China is one of Boehringer Ingelheim's key markets and innovation hubs. The company integrates the needs of Chinese patients into its global research and development strategy, striving to bring more innovative products to Chinese patients sooner, contribute to the high-quality development of China's healthcare industry, and comprehensively improve the health of humans and animals. 

Contact Us

Shanghai WD Pharmaceutical Co., Ltd.

Address:720 Cailun Road, Suite 403,Building 1, Zhangiiang Hi-Tech Park, Pudong New District, Shanghai, China(R&D Center)
Zip code:201203